Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ariella who wrote (1248)	9/17/1998 10:23:00 PM
From: NeuroInvestment	of 1491

Ariella: Your report was thorough and very appreciated. Apparently PARS management does play poker well, because they have indeed unblinded the data and have at least some of the findings analyzed in preliminary fashion.While Dr. Aviv is correct that there has been too much focus on the mortality endpoint (since with the small n, and small number of deaths, it would be hard to reach statistical significance)--PARS has only itself to blame, since they chose to publicize the 12.5% overall mortality rate, and its possible implications. Besides, the FDA loves mortality, because it is easy to measure. Since the Glasgow Coma Scale is such a time-honored medical categorical measure,those scores are critical--though this Phase II needs to impress corporate partners more than the FDA. The FDA is not fond of the kinds of functional measures involved in disability ratings--even though from a clinical/societal cost point of view, these could be the most important. I suspect that these more complicated datasets have not all been worked through yet. Thank you again. NeuroInvestment (www.neuroinv.com)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next